Christian Schade - Mar 10, 2022 Form 4 Insider Report for Aprea Therapeutics, Inc. (APRE)

Role
Chairman & CEO, Director
Signature
/s/ Scott M. Coiante, attorney-in-fact
Stock symbol
APRE
Transactions as of
Mar 10, 2022
Transactions value $
$0
Form type
4
Date filed
3/14/2022, 05:03 PM
Previous filing
Mar 1, 2022
Next filing
May 17, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction APRE Common Stock Award $0 +100K +64.57% $0.00 255K Mar 10, 2022 Direct F1
holding APRE Common Stock 1K Mar 10, 2022 By adult child F3
holding APRE Common Stock 1K Mar 10, 2022 By adult child F3
holding APRE Common Stock 1K Mar 10, 2022 By adult child F3
holding APRE Common Stock 1K Mar 10, 2022 By adult child F3
holding APRE Common Stock 1K Mar 10, 2022 By adult child F3
holding APRE Common Stock 1K Mar 10, 2022 By adult child F3
holding APRE Common Stock 5K Mar 10, 2022 By spouse

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction APRE Stock Option (right to Buy) Award $0 +428K $0.00 428K Mar 10, 2022 Common Stock 428K $1.82 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These shares represent restricted stock units which were granted on March 10, 2022, and which will vest and be settled in common stock as follows: (i) 33,366 shares on March 10, 2023, (ii) 33,367 shares on March 10, 2024 and (iii) 33,367 shares on March 10, 2025, subject to the reporting person's continued employment through and including the applicable vesting dates and subject to acceleration under certain conditions.
F2 Twenty-five percent of these options vest on March 10, 2023, with the remaining options vesting ratably over the following 36 months, subject to the reporting person's continued employment through and including the applicable vesting dates and subject to acceleration under certain conditions.
F3 The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, or for any other purpose.